利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.025 秒)

    METHOD FOR EVALUATING THE RESPONSE OF AN INDIVIDUAL TO A TREATMENT WITH A TYPE I INTERFERON (IFN)
    1.
    发明申请
    METHOD FOR EVALUATING THE RESPONSE OF AN INDIVIDUAL TO A TREATMENT WITH A TYPE I INTERFERON (IFN) 失效
    用于评估个体对I型干扰素（IFN）的治疗反应的方法

    公开(公告)号：US20100129788A1

    公开(公告)日：2010-05-27

    申请号：US12522623

    申请日：2008-01-24

    申请人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

    发明人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

    IPC分类号： C12Q1/70

    CPC分类号： C12Q1/707 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably M×A, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

    摘要翻译： 描述了用于评估在I型干扰素治疗的个体中预防I型（IFN）的生物学作用的因子的体内存在的方法。 在用I型干扰素治疗的个体中评估针对I型干扰素（IFN）的抗体的体内存在。 该方法包括将体外血液样品与适量的I型干扰素孵育合适的时间，并测定血液样品中IFN活性，优选M×A的生物学标志物的mRNA水平。 该治疗可涉及使用I型干扰素治疗多发性硬化症，HCV或HBV。

    Method to determine in vivo nucleic acid levels
    3.
    发明申请
    Method to determine in vivo nucleic acid levels 审中-公开
    确定体内核酸水平的方法

    公开(公告)号：US20050153292A1

    公开(公告)日：2005-07-14

    申请号：US10501666

    申请日：2003-01-20

    申请人： Patrick Stordeur ,  Michel Goldman

    发明人： Patrick Stordeur ,  Michel Goldman

    IPC分类号： C12N15/09 ,  C12N15/10 ,  C12Q1/68 ,  C12Q1/6806 ,  C12N1/08

    CPC分类号： C12N15/1003 ,  C12Q1/6806

    摘要： The invention in particular relates to a method for the quantification of in vivo RNA from a biological sample comprising the steps of: collecting said biological sample in a tube comprising a compound inhibiting RNA degradation and/or gene induction; forming a precipate comprising nucleic acids; separating said precipate from the supernatant; dissolving said precipitate using a buffer, forming a suspension; isolating nucleic acids from said suspension using an automated device; dispersing/distributing a reagent mix for RT-PCR using an automated device; dispersing/distributing the isolated nucleic acids within the dispersed reagent mix using an automated device, and determining the in vivo levels of transcripts using the nucleic acid/RT-PCR reagent mix in an automated setup. The present invention also relates to the quantitatification of DNA from a biological sample. The present invention further elucidates a kit for isolating quantifiable nucleic acids from a biological sample. Applications of the method according to present invention are aldo disclosed.

    摘要翻译： 本发明特别涉及一种用于从生物样品中定量体内RNA的方法，包括以下步骤：在包含抑制RNA降解和/或基因诱导的化合物的管中收集所述生物样品; 形成包含核酸的沉淀物; 将上述沉淀物与上清液分离; 用缓冲液溶解所述沉淀物，形成悬浮液; 使用自动化装置从所述悬浮液中分离核酸; 使用自动化装置分散/分配用于RT-PCR的试剂混​​合物; 使用自动化装置将分离的核酸分散/分散在分散的试剂混合物中，并且在自动设置中使用核酸/ RT-PCR试剂混合物确定转录物的体内水平。 本发明还涉及来自生物样品的DNA的定量化。 本发明进一步阐明了用于从生物样品中分离可量化核酸的试剂盒。 根据本发明的方法的应用是公开的。

    Method for evaluating the response of an individual to a treatment with a type I interferon (IFN)
    5.
    发明授权
    Method for evaluating the response of an individual to a treatment with a type I interferon (IFN) 失效
    评价个体对I型干扰素（IFN）治疗反应的方法

    公开(公告)号：US08426170B2

    公开(公告)日：2013-04-23

    申请号：US12522623

    申请日：2008-01-24

    申请人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

    发明人： Patrick Stordeur ,  Mathieu Vokaer ,  Annick Ocmant ,  Michel Goldman

    IPC分类号： C12P19/34

    CPC分类号： C12Q1/707 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably MxA, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

    摘要翻译： 描述了用于评估在I型干扰素治疗的个体中预防I型（IFN）的生物学作用的因子的体内存在的方法。 在用I型干扰素治疗的个体中评估针对I型干扰素（IFN）的抗体的体内存在。 该方法包括将体外血液样品与合适量的I型干扰素孵育合适的时间，并测定血液样品中IFN活性生物学标志物，优选MxA的mRNA水平。 该治疗可涉及使用I型干扰素治疗多发性硬化症，HCV或HBV。

    CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY
    6.
    发明申请
    CYTOKINES AS PROGNOSTIC MARKERS OF RESPIRATORY-TRACT INFECTION FOLLOWING MAJOR SURGERY 审中-公开
    细胞因子作为主要手术后呼吸道感染的预防标记

    公开(公告)号：US20120129176A1

    公开(公告)日：2012-05-24

    申请号：US13132127

    申请日：2009-11-30

    申请人： Thomas Ryan ,  Mary White ,  Owen Ross McManus ,  Dermot Kelleher ,  Patrick Stordeur ,  Vincent Young

    发明人： Thomas Ryan ,  Mary White ,  Owen Ross McManus ,  Dermot Kelleher ,  Patrick Stordeur ,  Vincent Young

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G16B20/00 ,  G16H50/30

    摘要： The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines IL-2, IL-7, IL-23, IL-27, and IL-IO, and Interferon-γ (INFγ) and Tissue Necrosis Factor-α (TNFα). The markers may be employed as individual prognostic variables of infection status, or they may be used in pairs or other combinations. Generally, the abundance of the markers is correlated with infection status by means of an absolute pre-operative value of biomarker abundance, ratio's of pre-operative to post-operative biomarker abundance, or ratio values for pairs of certain biomarkers within the subset. Typically, cytokine abundance is expressed in terms of mRNA copy number wherein the copy numbers are ideally normalised to a house keeping gene and quantification of mRNA copy number is determined by RT-PCR containing reference serial dilutions of cytokine specific cDNA.

    摘要翻译： 本发明涉及某些亚细胞因子标记物在个体中作为感染状态的预后变量的用途，特别是作为手术后发生严重感染如肺炎和呼吸道感染的患者的预后标志物。 细胞因子标志物亚群由IL-2，IL-7，IL-23，IL-27和IL-10以及干扰素-γ（INFγ）和组织坏死因子-α（TNFα）组成。 标记物可以用作感染状态的个体预后变量，或者它们可以成对使用或其它组合使用。 通常，标记物的丰度与生物标志物丰度的绝对术前价值，手术前与术后生物标志物丰度的比值或子集内特定生物标志物对的比值相关联于感染状态。 通常，细胞因子丰度以mRNA拷贝数表示，其中拷贝数理想地归一化为保存基因，并且通过含有细胞因子特异性cDNA的参考连续稀释度的RT-PCR测定mRNA拷贝数的定量。